Covered recipient · General Payments record
SANJAY YATHIRAJ
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$9,523.87
197 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,125.00 | 2 |
| Food and Beverage | $4,373.10 | 192 |
| Travel and Lodging | $25.77 | 3 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SANJAY YATHIRAJ
NPI 1508851718 · CMS profile ID 23074
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
BRADENTON, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SANJAY YATHIRAJ, NPI 1508851718, CMS profile ID 23074. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). SANJAY YATHIRAJ, NPI 1508851718, CMS profile ID 23074. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- SANJAY YATHIRAJ, NPI 1508851718, CMS profile ID 23074, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508851718?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
197 matching records · $9,523.87 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 197.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| UCB, Inc. | $10.14 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143127652 | CMS |
| PFIZER INC. | $8.44 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131430456 | CMS |
| ABBVIE INC. | $15.13 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373168 | CMS |
| ABBVIE INC. | $2,625.00 | 05/29/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373170 | CMS |
| Neurocrine Biosciences, Inc. | $5.43 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150887753 | CMS |
| Eisai Inc. | $19.22 | 05/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110779783 | CMS |
| Alnylam Pharmaceuticals Inc. | $21.95 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125826837 | CMS |
| PFIZER INC. | $22.77 | 05/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131479116 | CMS |
| Lilly USA, LLC | $18.22 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135413357 | CMS |
| Teva Pharmaceuticals USA, Inc. | $6.23 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151454159 | CMS |
| ARGENX US, INC. | $22.94 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142102240 | CMS |
| Teva Pharmaceuticals USA, Inc. | $7.33 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151454155 | CMS |
| Teva Pharmaceuticals USA, Inc. | $25.70 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151454157 | CMS |
| PFIZER INC. | $4.77 | 05/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131438265 | CMS |
| ABBVIE INC. | $15.17 | 05/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373166 | CMS |
| Biogen, Inc. | $20.72 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104823200 | CMS |
| Neurocrine Biosciences, Inc. | $7.84 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150884501 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.25 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137700782 | CMS |
| UCB, Inc. | $20.53 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143127643 | CMS |
| ABBVIE INC. | $121.98 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373162 | CMS |
| ABBVIE INC. | $12.06 | 05/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373164 | CMS |
| UCB, Inc. | $25.61 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155570791 | CMS |
| Neurocrine Biosciences, Inc. | $38.77 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150815802 | CMS |
| PFIZER INC. | $3.59 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131421261 | CMS |
| HARMONY BIOSCIENCES LLC | $32.51 | 04/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126061480 | CMS |
| LivaNova USA, Inc. | $14.60 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152791163 | CMS |
| LivaNova USA, Inc. | $13.84 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152791165 | CMS |
| ABBVIE INC. | $15.24 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373160 | CMS |
| Neurocrine Biosciences, Inc. | $124.64 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150809301 | CMS |
| Teva Pharmaceuticals USA, Inc. | $9.84 | 04/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151454141 | CMS |
| JAZZ PHARMACEUTICALS INC. | $15.04 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150218583 | CMS |
| Abbott Laboratories | $143.79 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125101732 | CMS |
| Inspire Medical Systems, Inc. | $18.84 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148129085 | CMS |
| Teva Pharmaceuticals USA, Inc. | $31.08 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151454139 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $25.09 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137700780 | CMS |
| Novartis Pharmaceuticals Corporation | $18.58 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346156 | CMS |
| Novartis Pharmaceuticals Corporation | $2.31 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346158 | CMS |
| Novartis Pharmaceuticals Corporation | $78.10 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087346160 | CMS |
| PFIZER INC. | $4.59 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131421257 | CMS |
| E.R. Squibb & Sons, L.L.C. | $33.96 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101760623 | CMS |
| ABBVIE INC. | $19.93 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373158 | CMS |
| Neurocrine Biosciences, Inc. | $5.62 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150887547 | CMS |
| Otsuka America Pharmaceutical, Inc. | $22.05 | 03/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119007533 | CMS |
| EMD Serono, Inc. | $19.79 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120238736 | CMS |
| GE HEALTHCARE | $24.81 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144682860 | CMS |
| ABBVIE INC. | $18.50 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373156 | CMS |
| PFIZER INC. | $5.22 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131420961 | CMS |
| PFIZER INC. | $23.99 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131235495 | CMS |
| GE HEALTHCARE | $19.52 | 03/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144681507 | CMS |
| ABBVIE INC. | $17.26 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106373154 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $497,201.07 | 37 |
| PY2024 | Principal investigator | $827,705.44 | 17 |
| PY2023 | Recipient | $150.00 | 1 |
| PY2023 | Principal investigator | $628,399.76 | 29 |
| PY2022 | Principal investigator | $170,009.58 | 7 |
| PY2021 | Recipient | $1,130.00 | 1 |
| PY2021 | Principal investigator | $48,658.99 | 426 |
| PY2020 | Recipient | $5,000.00 | 2 |
| PY2020 | Principal investigator | $22,844.76 | 4 |
| PY2019 | Recipient | $7,000.00 | 2 |
| PY2019 | Principal investigator | $29,433.65 | 13 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
37 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $1,962.84 | 12/09/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304367 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $524.00 | 11/12/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304398 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,134.00 | 11/12/2025 | Non-covered Recipient Entity NOVA CLINICAL RESEARCH LLC | A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care | No dispute reported | 06/30/2026 | 1223288195 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,134.00 | 11/12/2025 | Non-covered Recipient Entity NOVA CLINICAL RESEARCH LLC | A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care | No dispute reported | 06/30/2026 | 1223288197 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $13.16 | 11/04/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304387 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $21.65 | 10/30/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304383 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $241.15 | 10/28/2025 | Non-covered Recipient Entity NOVA CLINICAL RESEARCH | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190308370 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 10/13/2025 | Non-covered Recipient Entity NOVA CLINICAL RESEARCH LLC | A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care | No dispute reported | 06/30/2026 | 1223286735 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $1,962.84 | 09/26/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304379 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $262.00 | 09/02/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304391 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $981.42 | 08/26/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304395 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $48,462.00 | 08/11/2025 | Non-covered Recipient Entity Nova Clinical Research | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647458 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $152,759.00 | 08/11/2025 | Non-covered Recipient Entity Nova Clinical Research | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647460 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $981.42 | 08/06/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304372 |
| Principal investigator 1 | GENZYME CORPORATION | $33,300.00 | 08/04/2025 | Non-covered Recipient Entity Nova Clinical Research Bradenton | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226105177 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $5,715.00 | 07/25/2025 | Non-covered Recipient Entity NOVA CLINICAL RESEARCH | A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1185544519 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,065.39 | 07/14/2025 | Non-covered Recipient Entity Roskamp Institute | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) | No dispute reported | 06/30/2026 | 1235994145 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $32,525.00 | 05/20/2025 | Non-covered Recipient Entity Nova Clinical Research | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647454 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $981.42 | 05/07/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304330 |
| Principal investigator 1 | Eli Lilly and Company | $2,943.00 | 05/06/2025 | Non-covered Recipient Entity ROSKAMP INSTITUTE INC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187887814 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $59,784.00 | 04/10/2025 | Non-covered Recipient Entity Nova Clinical Research | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647456 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,154.80 | 03/20/2025 | Non-covered Recipient Entity THE ROSKAMP INSTITUTE INC | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190313457 |
| Principal investigator 1 | Sage Therapeutics, LLC | $4,428.02 | 03/06/2025 | Non-covered Recipient Entity BRADENTON RESEARCH CENTER INC | Study to Evaluate SAGE-324 in Participants With Essential Tremors | No dispute reported | 06/30/2026 | 1206580205 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,750.00 | 02/27/2025 | Non-covered Recipient Entity NOVA CLINICAL RESEARCH LLC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190304857 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $2,926.02 | 02/11/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304335 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $34.42 | 02/11/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304347 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $43.30 | 02/11/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304352 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $13.40 | 02/11/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304356 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $5,816.46 | 02/11/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304360 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $32.90 | 02/11/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304364 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $524.00 | 02/07/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304326 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $4,907.10 | 02/07/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304340 |
| Principal investigator 1 | Pacira Pharmaceuticals Incorporated | $1,962.84 | 02/07/2025 | Non-covered Recipient Entity Nova Clinical Research, LLC | A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | No dispute reported | 06/30/2026 | 1250304344 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,356.95 | 01/09/2025 | Non-covered Recipient Entity NOVA CLINICAL RESEARCH | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190308372 |
| Principal investigator 1 | Eli Lilly and Company | $213.25 | 01/07/2025 | Non-covered Recipient Entity ROSKAMP INSTITUTE INC | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | No dispute reported | 06/30/2026 | 1187887460 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $74,102.00 | 01/06/2025 | Non-covered Recipient Entity Nova Clinical Research | Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment | No dispute reported | 06/30/2026 | 1232647452 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $35,182.32 | 01/01/2025 | Non-covered Recipient Entity ROSKAMP INSTITUTE | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190305661 |